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Abstract
Background: We determined recently that dentin sialophosphoprotein (DSPP), a member of the SIBLING (Small integrin-
binding ligand N-linked glycoproteins) family of phosphoglycoproteins, is highly upregulated in human oral squamous cell
carcinomas (OSCCs) where upregulation is associated with tumor aggressiveness. To investigate the effects of DSPP-
silencing on the tumorigenic profiles of the oral cancer cell line, OSC2, short-hairpin RNA (shRNA) interference was
employed to silence DSPP in OSC2 cells.
Methodology/Principal Findings: Multiple regions of DSPP transcript were targeted for shRNA interference using hDSP-
shRNA lentiviral particles designed to silence DSPP gene expression. Control shRNA plasmid encoding a scrambled
sequence incapable of degrading any known cellular mRNA was used for negative control. Following puromycin selection
of stable lines of DSSP-silenced OSC2 cells, phenotypic hallmarks of oral carcinogenesis were assayed by western blot and
RT-PCR analyses, MTT (cell-viability), colony-formation, modified Boyden-Chamber (migration and invasion), and flow
cytometry (cell-cycle and apoptosis) analyses. DSPP-silenced OSC2 cells showed altered cell morphology, reduced viability,
decreased colony-formation ability, decreased migration and invasion, G0/G1 cell-cycle arrest, and increased tumor cell
sensitivity to cisplatin-induced apoptosis. Furthermore, MMP-2, MMP-3, MMP-9, VEGF, Ki-67, p53, and EGFR were down-
regulated. There was a direct correlation between the degree of DSPP-silencing and MMP suppression, as indicated by least
squares regression: MMP-2 {(y=0.850x, p,0.001) (y=1.156x, p,0.001)}, MMP-3 {(y=0.994x, p,0.001) (y=1.324x,
p=0.004)}, and MMP-9 {(y=1.248x, p=0.005, y=0.809, p=0.013)}.
Conclusions/Significance: DSPP-silencing in OSC2 cell decreased salient hallmarks of oral tumorigenesis and provides the
first functional evidence of a potential key role for DSPP in oral cancer biology. The down-regulation of MMP-2, MMP-3,
MMP-9, p53 and VEGF in DSPP-silenced OSC2 cells provides a significant functional/molecular framework for deciphering
the mechanisms of DSPP activities in oral cancer biology.
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Introduction
Dentin sialophosphoprotein (DSPP) is a member of the
SIBLING (Small Integrin-Binding LIgand N-linked Glycoprotein)
family of extracellular matrix glycophosphoproteins [1]. Other
members of the family are bone sialoprotein (BSP), dentin matrix
protein 1 (DMP1), dentin sialophosphoprotein (DSPP), osteopon-
tin (OPN), and matrix extracellular phosphoglycoprotein (MEPE)
[1]. Expression of the SIBLINGs was originally thought to be
limited to bone and teeth where they function to facilitate dentin
and bone matrix mineralization [1–3]. Recent reports however
indicate that the SIBLINGs are also present in non-mineralizing
metabolically active ductal epithelial cells of the salivary glands,
nephrons, and eccrine sweat glands where their function may be
associated with the repair of pericellular and extracellular matrix
(ECM) proteins damaged by free radical generated through
intense metabolic activity [4–6].
Earlier reports have identified the up-regulation of some
members of the SIBLINGs in various cancers, including breast,
lung, and prostate cancers [7]. OPN however is the SIBLING for
which there is unequivocal evidence for its role in many of the
steps of cancer development and progression [6–8]. Accumulating
data are beginning to implicate other family members, notably
BSP and DSPP, with roles in specific stages of tumor progression
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8]. We recently reported the up-regulation of BSP, DSPP, and
OPN, in human oral squamous cell carcinomas (OSCCs) [9] and
in some human oral epithelial dysplasia (OEDs) [10]. These
reports indicate that DSPP is highly up-regulated in poorly
differentiated and histologically aggressive OSCC [9]. Significant-
ly, OEDs expressing DSPP with or without BSP exhibited a 4-fold
propensity for transition to OSCC compared to OEDs expressing
BSP alone, suggesting that DSPP expression increased the risk of
local primary OSCC while BSP expression decreased such risk
[10]. However, there currently are no data on the functional and
mechanistic role of DSPP in oral cancer development and
progression.
In the present study designed to establish functional correlations
between DSPP expression and the biologic behavior of OSCC,
short hairpin RNA (shRNA) interference was used to produce
silencing of DSPP in OSCC cell line OSC2. DSPP-silenced OSC2
cells were then evaluated to determine the extent to which
silencing suppresses or abrogates key malignant phenotypic
characteristics of OSC2 cells using various standard in vitro
techniques.
Results
DSPP is upregulated in oral cancer cell lines, OSC2 and
SCC25, and in dysplastic oral epithelial cell line, DOK
OSC2 and SCC25 are human OSSC cell lines derived from
regional cervical lymph node metastasis of a primary human
tongue squamous cell carcinoma, and a primary tongue squamous
cell carcinoma, respectively [11–13]. DOK is a human oral
epithelial dysplastic cell line derived from dorsal tongue [14]. To
evaluate the endogenous expression levels of DSPP protein and
mRNA in OSC2, SCC25, and DOK cells, western blot and
semiquantitative-reverse transcriptase (RT)-PCR analyses were
carried out on whole-cell lysates and total RNA extracts,
respectively, as described in the Material and Methods. Positive
and negative controls consisted of whole-cell lysates and total RNA
extracts from MCF-7 cell (derived from mammary adenocarcino-
ma) and HOK cells (derived from primary culture of human oral
keratinocytes), respectively. DSPP is significantly upregulated in
OSC2, SCC25, and in DOK compared with HOK cells at the
translational (Figure 1A) and transcriptional (Figure 1B) levels.
These in vitro findings are consistent with the results of our recent
studies indicating the up-regulation of DSPP in OSCC from
patients, and its complete absence in normal oral mucosal
epithelium [9].
Transient DSP-shRNA transfection results in altered
morphology of OSC2 cells
Having established baseline expression levels of DSPP in two
OSCC cell lines, we proceeded to investigate how stable DSPP-
silencing via lentiviral-mediated small hairpin RNA (shRNA)
interference affects the tumorigenic profiles of OSC2 cells. We
chose OSC2 cells over their SCC25 counterpart because of the
demonstrably higher expression levels of DSPP in OSC2 cells at
both the protein and mRNA levels (Figure 1) and also because
OSC2 cells exhibit very strong invasive phenotype as evidenced in
experimental nude mouse models [11–13]. In order to assess the
immediate effects of DSP-shRNA transfection on OSC2 cell
morphology, transfected cells along with controls were photo-
graphed at 24- and 48-hr post-transfection (transient stage) prior to
commencement of puromycin selection of stably transfected cells.
As shown in Figures 2C and 2F (illustrative areas photographed),
DSP-shRNA transfected OSC2 cells exhibited a by far greater
number of cells with considerable loss of the cell-cell contact and a
more ovoid and irregular outline compared with non-transfected
OSC2 cells (Figure 2A) or scrambled sequence controls
(Figures 2B, 2E). Fluorescence microscopy of transiently trans-
fected coGFP-shRNA clones showed a strong green fluorescence
indicative of high percentage transfection efficiency (Figure 2D).
We proceeded to establish stable DSP-shRNA-silenced OSC2 cells
via puromycin selection in order to investigate the extent of any
changes in other salient phenotypic hallmarks of OSCC.
Generation of a stable DSPP-silenced OSC2 cell line
Stable lines of DSP-silenced and scrambled sequence controls
were selected by means of puromycin antibiotics as described in
Materials and Methods. The effectiveness of DSP-shRNA
lentiviral construct in stably silencing DSPP in OSC2 cells was
verified by western blot and quantitative real-time PCR (qRT-
PCR) analyses. As shown in Figure 3, western blot and
densitometric analyses of six different DSP-shRNA transfected
OSC2 stable lines showed DSPP silencing ranging from ,5%
[Line (L) 4] to ,95% L2 compared with stable shRNA-scrambled
sequence (shC) control (Figure 3A). These results were further
confirmed by immunofluorescence confocal microscopy showing
significantly reduced DSPP signal (green fluorescence) in L2 stable
lines compared with control (Figure 3C).
In parallel, we verified the effectiveness of DSP-shRNA in
depleting DSPP mRNA in lentivirally infected cells by qRT-PCR
using L1 and L2 exhibiting the most knockdown of the six lines
(see Figure 3A) on western blot. The results indicate significantly
reduced DSPP mRNA levels in L1 (.99%) and L2 (.95%)
compared with shRNA shC control line (Figure 3B). The CT
values obtained from qRT-PCR analysis of the relative DSPP
mRNA levels in shC control and DSPP-silenced L1 and L2 were
normalized with the housekeeping gene GAPDH. This shRNA-
mediated effect was specific, as GAPDH levels did not differ
significantly amongst the DSP-shRNA transfected cells and
controls.
DSPP-silencing reduces p53, Ki-67 and PCNA, and inhibits
cell proliferation and colony-formation in OSC2 cells
The effects of DSPP-silencing on the levels of proliferative
marker, Ki-67, PCNA, and the cell cycle regulator p53 were
analyzed by western blot for all six DSPP-silenced OSC2 stable
lines. Compared with ShC control line, the levels of Ki-67, PCNA,
and p53 were significantly reduced, indicating that DSPP may
enhance proliferation in oral cancer cells via mechanisms
involving p53, Ki-67, and PCNA (Figure 4A).
In order to determine the extent to which DSPP silencing affects
the proliferation of OSC2 cells, we carried out MTT assays for
three of the six DSPP-silenced stable lines that included L2
demonstrating the highest degree of DSPP-silencing, L4 demon-
strating the least silencing, and L6 demonstrating moderate
silencing. Compared with shC control and parental OSC2 cell
lines, silencing of DSPP was associated with an average of 53%
decrease in cell proliferation at day 6 in L2 (Figure 4B; P,0.05;
n=3). With respect to the ability to form colonies, L2 cells formed
colonies in soft agar that were considerably smaller and fewer than
those from shC controls, and from parental OSC2 cells
(Figure 4C). The number of colonies formed in L2 cells was
significantly reduced (,25% of parent OSC2 cells and about 20%
of shC control) as shown in Figure 4C bar graph. These results
suggest a significant role for DSPP in oral cancer cell growth and
proliferation. L2 cells demonstrating the most significant degree of
DSPP-silencing of all six lines were employed for investigations of
DSPP in Oral Carcinogenesis
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activities.
DSPP-silencing decreases OSC2 migration and invasion
As described in the Material and Methods section, we carried
out invasion and migration assays using modified Boyden
Chamber experiments in order to determine the extent to which
DSPP silencing affects migration and invasion of OSC2 cells. As
shown in Figure 5, silencing of DSPP (L2) decreased invasion
(Figure 5A) and migration (Figure 5B) of OSC2 cell by 25% in
each case, compared with shC control and parental OSC2 cells
(p,0.05 for each comparison using Dunn method of multiple
comparisons). Based on these findings we hypothesize that DSPP
plays a significant role in migration and invasiveness within OSCC
microenvironment to at least aid local spread of tumor.
Furthermore, the results of these in vitro assays allow us to
speculate that DSPP may play a role in distant site metastasis of
primary OSCCs.
Stable DSPP-silencing in OSC2 cells induces G0/G1 arrest
To verify the effects of DSPP suppression on OSC2 cell cycle
activities, flow cytometric analysis of DSPP-silenced OSC2 stable
line, L2, was carried out. The proportion of L2 cells in the G0/G1
phase was significantly increased compared with that of shC
control and that of parental OSC2 cells (Figure 6). As shown in
Figure 6A, 79.51% of L2 cells accumulated in the G0/G1 phase in
contrast with 44.77% and 45.98 of parental OSC2 and shC
controls, respectively. The proportions of cells in the S and G2/M
phases of L2 cells were 14.62% and 5.88%, respectively, compared
with 30.74% (S) and 24.49% (G2/M) for parental OSC2 cells, and
32.92% (S) and 21.11% (G2/M) for shC control cells. However,
there were no detectable differences in apoptotic rate between L2
cells and shC controls as further confirmed by DNA laddering
experiments (Figure 6B), indicating that DSPP-silencing alone does
not increase the apoptosis rate in OSC2 cells.
Stable DSPP-silencing sensitized OSC2 cells to cisplatin-
induced apoptosis
Head and neck squamous cells carcinomas (HNSCC), including
OSCCs, develop acquired or intrinsic resistance to cisplatin-based
combination chemotherapy [15,16]. It has been suggested that the
mechanism of interference with cisplatin-induced apoptosis in
HNSCCs is by upregulation of EGFR [15]. We therefore sought
to determine the effect of DSPP-silencing on EGFR expression as
well as the extent of the effects of DSPP-silencing on response of
OSC2 cells to cisplatin-induced apoptosis.
Following treatment of DSPP-silenced OSC2 (L2) cells and
controls (parental OSC2 and shC) with various doses of cisplatin in
a time-course experiment as described in the Material and
Methods section, rate of apoptosis in L2 cells was analyzed by
Annexin V/FITC flow cytometry, and compared with rates in
controls. With almost 100% of cells gated and FACS sorted,
Figure 1. DSPP upregulation in oral-cancer cells, OSC2 and SCC25, and the dysplastic oral keratinocyte cells, DOK. (A) Western blot
(WB) and densitometric analyses show significant upregulation of DSPP in OSC2, SCC25, and DOK cells compared with HOK negative controls. There
is a basal (,10%) level of DSPP expression in primary HOK cells. MCF7 cell line known to express DSPP was used as positive control. Normalization
was with b-actin. (B) Semiquantitative RT-PCR analysis shows DSPP-mRNA expression in OSC2, SCC25, and DOK cells consistent with WB results in (A)
with undetectable DSPP-mRNA levels in HOK cell. Normalization was with GAPDH. Cells used in study: OSC2, a human OSCC cell line derived from
regional cervical lymph node metastasis of a primary human tongue squamous cell carcinoma; SCC25, a primary tongue squamous cell carcinoma;
DOK, a human oral epithelial dysplastic cell line derived from dorsal tongue; and MCF7 (acronym of Michigan Cancer Foundation – 7), a human
breast cancer cell line isolated from a 69-year-old Caucasian female.
doi:10.1371/journal.pone.0013974.g001
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increased from 41.28% in parental OSC2 cells (and 43.69% in
shC controls) treated with 50 uM cisplatin for 24 hrs to 56.19% in
L2 cells treated with equal dose of cisplatin. On the other hand,
the apoptotic cell fractions without cisplatin for OSC2 (9.63%),
ShC control (12.81%), and L2 cells (13.99%) were not significantly
different. Similarly, results of trypan blue staining indicate equally
significant increase in the rate of apoptosis in L2 cells treated with
cisplatin compared with shC control and parental OSC2 cells
treated with cisplatin at various doses (Figure 7B).
Furthermore, the level of EGFR was significantly reduced in L2
cells compared to shC controls, suggesting that EGFR inhibition is
required for cisplatin-induced apoptosis in OSC2 cells (Figure 7C).
Collectively, these results suggest that DSPP silencing in OSC2
cells, while resulting in G0/G1 arrest (see Figure 6A) and therefore
reduced proliferative activity, does not increase apoptosis;
however, DSPP suppression may significantly enhance the
sensitivity of OSC2 cells to cisplatin-induced apoptosis via
mechanism involving the downregulation of EGFR.
Stable DSPP-silencing in OSC2 cells suppresses MMP-2,
MMP-3, and MMP-9 expressions
Earlier reports have identified specific interactions between
some members of the SIBLING family of proteins with specific
matrix metalloproteinases (MMPs). Specifically, BSP partners with
proMMP-2, OPN with proMMP-3, and DMP-1 with proMMP9
in order to activate the respective proteases [4,17]. However, the
MMP partner(s) to DSPP and MEPE, if any, have not been
identified. Nevertheless, we sought to determine the expression
status of these three known SIBLING-partnering MMPs in all six
generated DSPP-silenced OSC2 lines.
As shown by western blot and densitometric analyses, levels of
both pro- and activated MMP-2, MMP-3, and MMP-9 levels were
reduced in all but one of the six DSPP-silenced OSC2 lines
compared with shC controls (Figures 8A, 8B). Equally significant is
a direct correlation between the degree of DSPP-silencing and
MMP suppression, as indicated by least squares regression analysis
through the origin: MMP-2 {(y=0.850x, p,0.001) (y=1.156x,
p,0.001)}, MMP-3 {(y=0.994x, p,0.001) (y=1.324x,
p=0.004)}, and MMP-9 {(y=1.248x, p=0.005, y 0.809,
p=0.013); Figure 8C)}. However, the level of MMP suppression
did not differ significantly between pro- and cleaved forms.
Similarly, decrease in VEGF levels in stable DSPP-silenced lines
ranged from ,5% (L4) to 86% (L2) with the level of suppression
directly proportional to the degree of DSPP-silencing (Figure 8D),
suggesting a dose-dependent relationship between DSPP expres-
sion and angiogenic activity in OSCCs. Collectively, these results
suggest a regulatory role for DSPP in the upregulation and
activation of the SIBLING-partnering MMPs as well as angio-
genesis in oral cancer.
In vivo anti-tumor effects of DSPP-silencing on OSC2 cells
The anti-tumor effect of DSPP-silencing in OSC2 cells was
tested in two Balb/c nude mice implanted subcutaneously with
DSPP-silenced OSC2 cells (L2 lines) on the left flank, while the
scrambled sequence control (shC lines) was implanted subcutane-
ously on the right flank. As shown in the Supplementary Figure
S1, a trend towards slowed tumor development and growth
Figure 2. Transient lentiviral-mediated DSP-shRNA knockdown results in altered morphology of OSC2 cells. (A) OSC2 cells prior to
lentiviral-transduced transfection with DSP-ShRNA exhibiting characteristic morphology of viable epithelial tumor cells in culture. (B, E) Scrambled
(control) sequence-transfected OSC2 cells at 24- and 48 h exhibiting viable epithelial cells and morphology comparable to (A). (C, F; illustrative areas)
DSP-shRNA transfection OSC2 cells exhibiting significantly increased number of cells with loss of cell-cell contact, more rounded and irregular outline,
prominent nuclear blebbing, and cellular disintegration consistent with those of effete and dying cells at 24- and 48-h, respectively. (D) copGFP
transfected OSC2 cells confirm very high transfection efficiency (green fluorescence).
doi:10.1371/journal.pone.0013974.g002
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tumor compared with shC control tumors over a period of 6 weeks
[Figures S1A and S1G (scatter plot]. Histologic evaluation of
hematoxylene and eosin (H&E) sections showed well differentiated
and aggressive squamous cell carcinoma associated with the shC
(control) derived tumors (Figure S1B) compared with the less-
differentiated L2 derived tumors (Figure S1C). In addition, L2
derived tumors tended to form in small shrinking islands with
more visible tumor necrosis than shC derived tumors (Figure S1C).
Significantly, immuostain for DSPP verified DSPP reduction in L2
derived tumors (Figure S1E) compared with high DSPP level in
shC derived tumors (Figure S1D). Figure S1F is a representative
pre-immune IgG negative control. These results suggested that the
reduced tumorigenic hallmarks of OSCC following DSPP-silencing
observed in the in vitro experiments described above are
reproducible in vivo.
Discussion
This study, aimed at gaining insights into the functional role of
DSPP in the biology of oral cancer, was designed as a logical
sequel to our earlier reports indicating that DSPP is highly
upregulated in aggressive human OSCCs [6] and in those OEDs
with significantly high propensity for transition to invasive OSCC
[10]. To the best of our knowledge, our present report represents
the first demonstrating the upregulation of DSPP in two oral
cancer cell lines compared to, at best, basal level in primary
normal oral keratinocytes (NOK). More significantly, this is the
first report on a study that investigated the effects of DSPP-
silencing on the tumorigenic profiles of an oral cancer cell line.
DSPP, the largest member of the SIBLING gene family, encodes
a ,1300-amino acid protein post-translationally cleaved into two
major proteins, dentin sialoprotein (DSP) and dentin phosphopro-
tein (DPP, also called phosphorin) [2,18–20]. The expression of
DSP and DPP was originally thought to be limited to dentin (and
odontoblasts), where they play a major role in mineralization, with
DPP being the more abundant of the two proteins [2,19,21].
However, subsequent studies showed that lower level of DSPP
expression is present in bone [1–3]. Recent studies also have shown
significant levels of expression of DSPP (and other members of the
SIBLING family) in metabolically active ductal epithelial cells [4–
6], and its upregulation in a subset of breast, oral, lung, and prostate
cancers [6–9]. Because DSPP contains the highly conserved
MQXDPP motif that has been shown in DMP1 to be involved in
proteolytic processing, it has been hypothesized that the same
tolloid-related proteases (particularly BMP1) cleave DSPP into DSP
and DPP [19,20]. Proteolytic processing of DSPP by MMP-2,
MMP-20, and kallikrein-related peptidase 4 has been reported [19].
Figure 3. Generation of stable DSPP-silenced OSC2 cell lines. Stable lines selection of lentiviral-transduced shRNA was accomplished via
puromycine selection. (A) WB and corresponding densitometric analyses of level of DSPP-silencing following selection of six stable lines show levelo f
silencing ranging from ,5% (line [L] 4) to ,95% (L2) compared to scrambled sequence (shC) control. (B) qRT-PCR analysis show significantly reduced
DSPP-mRNA in DSPP-silenced L1 (.90%) and L2 (.95%) cells (exhibiting the most knockdown on WB) compared to shC control. (C)
Immunfluorescence confocal microscopy verifies DSPP-silencing as significantly reduced DSPP signal (green fluorescence) in L2.
doi:10.1371/journal.pone.0013974.g003
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recognizes both the full-length (DSPP) and the DPP portion but
not the DSP. The 97 kDa protein band in Figure 1A is indicative
of a cleavage product, DPP, but lower molecular weight bands
that would represent DSP were not present. Furthermore,
molecular weight band approximating that of the full length
DSPP was absent. Following silencing with a construct design that
targeted the full length DSPP, only very low levels of the 97KD
band was seen in most of the stable lines, indicating the silencing of
DPP and full length DSPP. While it is conceivable that our
knockdown strategy also might have reduced DSP levels, we
cannot determine, based on our present data, whether or not the
various effects of knockdown on the tumorigenic profile of OSC2
cells described were the result of decreased levels of DPP, DSP, or
both (or even intact DSPP). It is nonetheless highly suggestive at
this point that, in the least, DPP or its modified forms may play a
role in the tumorigenic regulatory activities of oral cancer cells.
Further studies, including strategies (e. g. adding some furin
inhibitors; see Ref. [20]) that causes the cells to secrete only full
length DSPP that could be used as a standard will be required for
subsequent inquiries addressing any specific mechanistic role for
DPP, DSP or the full length DSPP in the biology of oral cancers.
Reviews of the specific genes products profiled in this study,
following DSPP silencing, indicate that none of them have, until
now, been associated with the potential role of DSPP in oral
cancer. As a secreted protein DSPP represents an ideal target for a
shRNA-mediated silencing, and by analyzing the functional effects
of DSPP-silencing in OSC2, we show that DSPP-silencing down-
regulates key proteins involved in tumor cell proliferation,
angiogenesis, and local invasion. Specifically, our data show that
silencing of DSPP in oral cancer cells is associated with significant
down-regulation of the SIBLING-partnering MMPs, VEGF, p53,
and the cell proliferation markers Ki-67 and PCNA. Up-
regulations of MMP-2, MMP-3, MMP-9, VEGF, and p53 with
levels correlating with outcome and prognostic parameters such as
advanced disease stage, invasion, and metastasis have previously
been associated with oral cancer [22–24]. Thus, our results
indicating a significant down-regulation of MMP-2, MMP-3,
MMP-9, VEGF, and p53 following stable DSPP-silencing in OSC2
cells suggests that DSPP may operate upstream of these protein
Figure 4. DSPP-silencing results in dowregulation of Ki-67, PCNA, p53, and inhibition of cell proliferation and colony-formation. (A)
WB of ki-67, PCNA, and p53 following DSPP-silencing in OSC2 cells show significant downregulation for each of these proteins. (B) The proliferation
status of DSPP-silenced OSC2 cells compared to parental OSC2 and shC control carried out via MTT assay shows decreased cell proliferation of 53%
for L2 (demonstrating the most degree of silencing) compared with ,5% for L4 (least silencing), and ,30% for L6 (moderate silencing) and shC
control (p,0.05; n=3). (C) L2 cells formed smaller and significantly fewer (,25%) colonies in soft agar compared with parental OSC2 and shC control
cells (*p,0.05).
doi:10.1371/journal.pone.0013974.g004
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DSPP may directly, or at least remotely, regulate aspects of the
cell-cycle activity.
Recent reports also suggest that MMP-mediated remodeling of
extracellular matrix (ECM) is, indeed, one of several initiating
events allowing OSCC cells to invade the surrounding stroma
[25]. It is postulated that early expression of MMP by tumor or
surrounding stromal cells facilitates the remodeling of ECM,
resulting in the release of growth factors to ensure a viable nidus
for primary tumor growth [26,27]. In turn, tumor growth leads to
angiogenic switch during which the balance of proangiogenic
factors such as VEGF overcomes the expression of angiogenic
inhibitors [28]. VEGF-mediated angiogenesis is a hallmark of
OSCC progression [25,29], and MMP-2 and MMP-9 have both
been implicated in the induction of the angiogenic switch in
different models [26,27]. Although, the MMP partners of DSPP
and MEPE are yet to be identified, the dynamics and implications
of the SIBLING-MMP interaction in biologic systems is now one
of heightened research interest. For example, a recent report
indicated that in vitro invasiveness of some cancer cell lines was
enhanced via the formation of RGD-dependent complex with
MMP-2 and aVb3 integrin [30].
The resistance of head and neck squamous cell carcinomas
(HNSCC), including OSCCs, to chemotherapeutic agents such as
cisplatin is well documented and remains a major challenge to
effective chemotherapeutic interventions in OSCCs [15,16].
Cisplatin is effective in only about 20% of HNSCC patients. In
cancers of other systems with recorded chemotherapeutic
successes with cisplatin, the mechanism of action of cisplatin
adduced includes the induction of apoptosis in cancer cells [15].
The resistance of OSCC to cisplatin-induced apoptosis has been
attributed to the up-regulation of EGFR in HNSCCs [15]. Our
present data indicate that DSPP suppression alone, while
resulting in G0/G1 arrest, does not increase tumor cell death
by apoptosis in OSC2 cells. Our observation that the sensitivity of
OSC2 cells to cisplatin-induced apoptosis is significantly en-
hanced following DSPP-silencing, possibly through a mechanism
involving the downregulation of EGFR, is therefore both
significant and novel.
The in vivo anti-tumor effects of DSPP–silencing, while so far
demonstrated in only two mice, nevertheless, suggested a trend
towards reduced tumor growth. Elaborate design beyond the
scope of the present study will further verify this trend in the
context of other questions.
Collectively our present data showing that DSPP-silencing is
associated with significant alteration in notable hallmarks of oral
malignancy in OSC2 cells suggest that DSPP regulates multiple
pathways involving the SIBLING-partnering MMPs, VEGF, and
proliferation markers critical for oral cancer local progression and
metastatic spread. While a detailed study of the mechanism of
Figure 5. DSPP silencing decreased OSC2 migration and invasion. (A, B) Modified Boyden-Chamber experiment shows that DSPP-silencing in
(L2) decreased invasion (A) and migration (B) of OSC2 cells by ,25%, respectively, compared to shC control and parental OSC2 cells (for each
comparison using Dunn methods of multiple comparisons).
doi:10.1371/journal.pone.0013974.g005
DSPP in Oral Carcinogenesis
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13974DSPP-oral cancer tumorigenesis was beyond the scope of our
present report, our current data provides a framework for on-
going study focused on deciphering DSPP mechanistic network
involved in oral cancer biology. This, in turn, is with a view to
identifying target points for the design of potent biomimetics for
intervention in oral cancer.
Materials and Methods
Human Cell lines and culture conditions
The following human cell lines used in this study, SCC25 and
OSC2 (OSCC), and DOK (dysplastic oral keratinocytes) have
been published, and were initially obtained from American Type
Culture Collection. Mammary adenocarcinoma MCF7 cell whole
lysate was purchased form Santa Cruz Biotechnology (Santa Cruz,
CA; Cat. #sc-2206), while human oral keratinocyte (HOK) whole
lysate was purchased from ScienCell
TM Research Laboratories
(cat. #2616; San Diego, CA). All cell lines were routinely cultured
as monolayer in DMEM/F12 medium containing 10% FBS
(Invitrogen, Carlsbad, CA) supplemented with 1% Penicillin/
Streptomycin and 500 ng/ml Hydrocortisone (Sigma Aldrich, St.
Louis, MO) and maintained in the presence of 5% CO2
humidified air at 37uC.
Antibodies
Anti-DSPP monoclonal (LF-Mb21) and polyclonal (LF-151)
antibodies as well as polyclonal antibodies to MMP-2 (LF-83),
MMP-3 (LF-82), and MMP-9 (LF-84), which were kind gifts from
Dr. Larry W. Fisher (NIDCR, NIH Bethesda, MD) were used for
immunofluorescence, western blot, and immunohistochemistry
analyses. The monoclonal antibody to DSPP (LF-21) is now
available from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Polyclonal Ki-67 Mouse (Cat # sc-15402), polyclonal p53 (cat.
#sc-6243), polyclonal PCNA (cat. #sc-7902), and polyclonal
VEGF (cat. # 57496) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA) and used for western blot
analyses.
shRNA lentiviral particle transduction
DSP-shRNA (h) lentiviral particle (cat #sc-40500-V) is a
transduction-ready pool of 3 target-specific constructs encoding
19–25nt (plus hairpin) shRNAs designed to silence DSPP gene
expression. copGFP Control Plasmid (cat # sc-108083) is a
transfection-ready lentiviral vector plasmid that encodes
copGFP fluorescent protein in mammalian cells, and used to
monitor delivery of shRNA lentiviral construct into cells
thereby gauging transfection efficiency. Control shRNA
Figure 6. DSPP-silencing reduces G0/G1 arrest in OSC2 cells. (A) Flow cytometric analysis shows proportion of DSPP-silenced L2 cells in G0/G1
phase significantly increased (79.51%) compared with parental OSC2 (44.7%) and shC controls (45.98%). (B) Conversely, DNA laddering experiments
shows no significant difference in rate of apoptosis between L2 cells and controls. This result indicates that DSPP-silencing alone does not increase
the rate of apoptosis in OSC2 cells.
doi:10.1371/journal.pone.0013974.g006
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encodes a scrambled shRNA sequence that will not result in
specific degradation of any known cellular mRNA. All three
plasmid constructs, and the transfection reagent Polybrene
(Cat. # sc-134220) were purchased from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). The sequences of DSP-
shRNA Vector Plasmid and Control shRNA Plasmid-A are as
follows:
sc-40500-V (A pool of 3 different shRNA plasmids)
N Sense: GCAAGAGAAUACCCAAGAU
N Antisense: AUCUUGGGUAUUCUCUUGC
N Sense: CGAGGGUAAUACAAGUGAA
N Antisense: UUCACUUGUAUUACCCUCG
N Sense: CCAAGAUAAGGGAAUAGAA
N Antisense: UUCUAUUCCCUUAUCUUGG
sc-108060 (Plasmid Control A)
TTCTCCGAACGTGTCACGTTTCAAGAGAACGTGA-
CACGTTCGGAGAATTTTT
Note: all sequences are provided in 59 R 39 orientation.
DSP shRNA lentival mediated transduction of OSC2 cells
A day prior to transfection, 1.5610
4 logarithmically growing
and healthy OSC2 cells were split into four equal groups each
plated in 6-well plate in antibiotic-free DMEM/F12 media
supplemented with 10% serum (Mediatech Inc. VA) to achieve
a 70–80% confluency overnight. The groups are the ‘‘medium-
only’’, ‘‘Control shRNA Plasmid-A’’ (scrambled sequence),
‘‘copGFP Control Plasmid’’, and the experimental DSP shRNA
Plasmid group. Transient transfection was carried out following
the manufacturer’s protocol.
Prior to transfection, cells were washed with shRNA transfec-
tion medium before adding 2 ml of medium containing 5 ug/ml
Polybrene (cat. # sc-134220) to each well. Thereafter 30 ul
(,30610
4 particles) of lentiviral particles, equivalent to multiplic-
ity of infection factor (MOI) 1, was added drop-wise to
corresponding well and incubated overnight under normal cell
culture conditions. Following incubation, medium containing
polybrene was removed and replaced with normal growth medium
(NGM), and the cells incubated for an additional 24 hrs under
Figure 7. DSPP-silencing sensitizes OSC2 cells to cisplatin-induced apoptosis. (A) Treatment of DSPP-silenced L2, parental OSC2, and shC
control cells with 50 uM for 24 h followed by Annexin V/FITC flow cytometry analysis show a 56.19% increase in apoptotic rate (measured by sub-G1
cellular DNA content) for L2 cells compared with 41.28% in parental with cisplatin and OSC2 and 43.69% in shC control with cisplatin. (B) Trypan blue
staining bar chart quantitation indicates comparable apoptotic rates to that in (A). (C) WB showing significant down-regulation of EGFR in DSPP-
silenced OSC2 cells, including L2. Symbols: Cis= cisplatin; L2= DSPP-silenced OSC2 cells line 2; OSC2= parental (without knockdown) osc2 cells,
M1=live cells; M2= deal cells.
doi:10.1371/journal.pone.0013974.g007
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photographs of cells.
Establishment of DSP-shRNA stably transfected OSC2
cells
Selection of OSC2 cells stably expressing DSP shRNA DNA and
the Control shRNA Plasmid-A was commenced 72 h post-
transfection following the manufacturer’s instructions (Santa Cruz
Biotechnology, Santa Cruz CA). Briefly, growth medium was
aspirated from the cells and replaced with fresh selection medium
containing 3 mg/mL of puromycin (cat # sc-108071; Santa Cruz
Biotecnology). Puromycin-containing medium was replaced every
2–3days with freshly prepared selection medium, and selection of
stable cells expressing DSP-shRNA or Control shRNA Plasmid-A
was completed aproximately 4 weeks from commencement of
selection. Stable cells were expanded, harvested, and prepared for
westernblotandquantitativereal-timePCR(QR-TPCR)analyses.
Semiquantitative RT-PCR
Total RNA was extracted from 1/3
rd of the cell pellets from
each group (experimental and control) using the RNEasy Plus
Mini kit (Qiagen, CA) following the manufacturer’s instructions.
1 mg of total RNA was used to reverse transcribe to cDNA using
the High Capacity Reverse Transcription Kit (Applied BioSys-
tems, CA) in a conventional Thermo cycler following the
manufacturer’s instructions. PCR reaction was performed using
the Promega’s GoTaq Green MasterMix reagent (cat. #M7122;
Promega, Madison WI) and the DSPP primer pair from Santa
Cruz Biotechnology (cat # 40500PR; Primer design amplified a
519 base amplicon from NM_014208. Exact primer sequences are
proprietary and not available from company). 100 ng of cDNA
was used for the 25 ml PCR reaction, and GAPDH was used as a
normalizing control. PCR products were then electrophoresed on
a 2% agarose gel in Tris-acetate-EDTA (TAE) buffer, stained with
ethidium bromide, and photographed. Densitometric analysis of
DSPP mRNA levels was performed.
Quantitative Real-Time PCR (Q RT-PCR) analysis
From total RNA isolated from cell extracts, reverse transcription
to cDNA was performed. The SybGREEN qPCR primers for
DSPP (cat. #HP210697) and GAPDH (cat.#HP205798), pur-
chased from Origene (Rockville, MD), and the SybGREEN
Figure 8. DSPP-silencing downregulates SIBLING-partnering MMPs in OSC2 cells. (A) WB and (B) corresponding densitometric analyses
show significant down-regulation of pro- and activated MMP-2, MMP-3, and MMP-9 in all but one (L4) of the six DSPP-silenced stable lines. (C) Least
square regression analyses show significantly reduced levels of pro-and activated MMP-2 {(y=0.850x, p,0.001) (y=1.156x, p,0.001)}; MMP-3
{(y=0.0.994x, p,0.001) (y=1.324x, p=0.004)}, and MMP-9 {(y=1.248x, p=0.005, y=0.809, p=0.013)}, and a direct correlation between the degree of
DSPP-silencing and MMP suppression; however, the level of MMP suppression did not differ significantly between pro- and cleaved forms. (D)
Densitometric analysis of WB of VEGF levels showed down-regulation ranging from ,5% (L4) to 86% (L2) with the level of down-regulation directly
proportional to the degree of DSPP-silencing.
doi:10.1371/journal.pone.0013974.g008
DSPP in Oral Carcinogenesis
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13974Mastermix purchased from Bio-Rad (cat.#170-8880; Hercules,
CA) were used to perform the reaction. The human Primer
qSTAR qpcr primer pairs against Homo sapiens gene DSPP
NM_014208 had the following sequence: Forward: CAACCA-
TAGAGAAAGCAAACGCG
Reverse: TTTCTGTTGCCACTGCTGGGAC; while the
human Primer qSTAR qpcr primer pairs against Homo sapiens
gene GAPDH gene had the following sequence:
Forward: GTCTCCTCTGACTTCAACAGCG
Reverse: ACCACCCTGTTGCTGTAGCCAA
Reactions were carried out on the Real Time PCR - 7300
model instrument from Applied Biosystems following the manu-
facturer’s protocol. A total reaction volume of 25 ul was prepared
using 1 ul of 25X primer, 12.5 ul of 2X Mastermix, 100 ng cDNA
and deionised water added to the desired volume. Data was
analyzed using the Comparative Ct method (DDCt) method for
Relative Quantification (RQ). Here, DCt was calculated as
Ct(GOI)-Ct(Control), where GOI is the Gene of Interest (DSPP)
and the Control is GAPDH. DDCt was calculated as DCt(GOI)-
DCt(NC), where NC is the scrambled shRNA control (shC).
Percent of gene remaining was calculated as 2exp-1DDCt. Finally,
percentage knockdown was determined from percentage of
residual gene.
Western blot-analysis
Total cell lysates prepared from 2/3
rd of cell pelletes from each
group (experimental and controls) were resolved on SDS–PAGE
gel using the Mini-Protean Tetra Cell unit at 100 V (Biorad, CA)
by standard protocol. Briefly, 25 mg of protein was loaded in each
lane and resolved on the appropriate percentage polyacrylamide
gels before transferring to polyvinylidene (PVDF) membranes
(Millipore, MA) at 100 mA constant current for 75 mins in the
Biorad Transfer unit. The membrane was thereafter incubated in
blocking solution consisting of 1:1 diluted Sea Block Blocking
solution (LI-COR, Biosciences, Lincoln, Nebraska) in 1x PBS, for
1 hour at RT. Membrane was then incubated in primary antibody
(e.g. anti-monoclonal DSPP antibody, LF-MB21) and anti-b-actin
monoclonal antibody (Sigma, St. Louis, MO) diluted in blocking
buffer (1:1000 and 1:5000, respectively) overnight at 4uC before
washing with 1x PBS-T for 565 mins. Thereafter, membrane was
incubated with IRDye 600 goat anti-mouse secondary antibody
(L-ICOR Biosciences) at 1:5000 dilution for 1 hr at RT, washed
with 1x PBS-T 465 mins, and with 1x PBS for 5 mins. Signal was
detected using the Infrared LI-COR Imaging system (LI-COR
Biosciences).
Transwell migration and invasion assays
The motility and invasiveness of DSPP-silenced L2 cells and
controls were evaluated using a modified Boyden Chamber assay.
The Chamber consisted of a 24-well transwell chambers with
upper and lower culture compartments separated by uncoated
polycarbonate membranes with 8-mm sized pores (Costar 3422,
Corning Inc., NY). The polycarbonate membranes remained
uncoated in chambers used for the migration assay, whereas the
membranes in chambers used for the invasion assays were coated
with 100 ml of 100 mg/ml of Matrigel
TM (Collaborative Biomed-
ical Products, Bedford, MA) prior to the invasion assay. Prior to
plating cells into the transwells, DMEM–0.1% BSA was incubated
in the top chamber of each transwell at 37uC for 1 h in order to
saturate non-specific binding sites. Cells were then resuspended in
growth media (5610
4 cells/100 ml) following trypsinization before
plating into the upper compartment of the migration or invasion
chambers. DMEM–10% FBS was placed into the bottom
compartment to act as a chemoattractant. After 24 h (for
migration) and 48 h (for invasion) incubation at 37uCi n5 %
CO2 humidified air, the cells were incubated in Calcein-AM
(molecular Probes) for another 1 h at 37uC before removing the
remaining cells in the upper compartment surface of the
membrane with a cotton swab. Cells that migrated through the
pores sticking to the under surface of the membrane were fixed
with 3.7% paraformaldehyde before staining with 0.2% crystal
violet dye. Quantitative estimates of the number of migrated/
invaded cells were carried out through colorimetric analysis with a
microplate reader (absorbance at 590 nm). Assays were carried out
in triplicate and results expressed as mean 6 SD. Photomicro-
graphs of representative results were taken as shown in the Results
section.
MTT assay
For MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoli-
um bromide] assay methods, cells were seeded in 96-well plate
(Costar, Corning Inc., NY) at a density of 2610
3/well. Cell growth
was assessed at days 1 through 6, each day by staining with
100 ml/well of sterile MTT solution (0.5 mg/ml, Sigma Chemical
Co., St Louis, MO) for 4 h at 37uC. Thereafter, cell were
incubated for 5 min in 100 ml/well of Tris-Formalin solution
before washing each well with 200 ml of double distilled water
(ddH2O). 100 ml of DMSO was then added to each well, and
vortexed (on lowest speed setting) for one minute. Absorbance
value was measured on a microplate reader (BioRad) at 562 nm
using 630 nm as reference. Assays were performed in triplicate
and data are expressed as mean 6 SD.
Colony-formation assay
Cells (1000/well) were suspended in 0.35% Bactoagar and
were plated onto a layer of 0.75% Bactoagar in DMEM-F12
containing 5% FBS in 6-well tissue culture plates (Corning,
Corning, NY). The agar-containing cells were allowed to solidify
o v e r n i g h ta t3 7 uCi n5 %C O 2 humidified atmosphere.
Additional DMEM-F12+5% FBS was overlaid on the agar
and the cells allowed to grow undisturbed for 3weeks. Visible
colonies (.50 cells) were counted with the aid of a dissecting
microscope.
Cell cycle and apoptosis analyses by flow cytometry
L2 cells and controls were harvested after tripsinization, fixed
with cold 70% ethanol, and stored at 4uC pending cell cycle
analyses. L2 cells were treated with 50 uM cisplatin for 24 h,
washed in 1XPBS before fixing in 70% ethanol overnight. Prior to
cell cycle analysis, cells were resuspended in PBS containing
RNase A (20 ug/mL, Sigma) and 20 mg/ml propidium iodide (PI;
Sigma), and then incubated at 37uC for 30 min before analyses for
PI fluorescence intensity using the Becton Dickinson FACsort flow
cytometer (Becton-Dickinson, Temse, Belgium). A total of 10,000
events were counted for each sample group. The relative
proportions of cells in the G0/G1, S, and G2/M phases of the
cell cycle were analyzed using FlowJo software (Tree Star,
Ashland, OR).
For apoptosis analyses, Annexin V/PI staining of cells was
carried out. Briefly, cells were washed with 1XPBS and
resuspended at 2610
6 cell/ml in Annexin V-binding buffer before
aliquoting the suspension into 100 ul/tube fractions. Thereafter,
5 ul of Annexin V FITC and 10 ul of PI buffer were added to each
tube before incubating in the dark for 15 min at RT. 400 ul of 1x
Annexin V-binding buffer was then added to each tube and flow
cytometric analysis carried out within one hour. Controls consisted
of unstained, Annexin-positive, and PI-positive cells.
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L2 and controls previously treated with 50 umol/l cisplatin for
48 h were harvested and lysed in lysis buffer [0.5% SDS,
100 mmol/l EDTA, 10 mmol/l Tris-HCl (pH 8.00] before
incubating overnight with proteinase K (20 mg/ml, Sigma) at
37uC and treated with RNase A (50 ug/ml, Sigma). DNA was
then extracted and precipitated using the phenol/chloroform and
ethanol method. Extracted DNA was then dissolved in TE buffer
[10 mmol/l Tris-HCl, 1 mmol/l EDTA (pH 8.0)] and analyzed
on a 1% agarose gel containing ethidium bromide (0.05 ug/ml,
Sigma). DNA was visualized and photographed under UV light.
Immunofluorescence
L2 cells and controls were grown in DMEM/Hams F-12
medium with 10% fetal calf serum, 100 IU/ml penicillin, 100 mg/
ml streptomycin, and 5 mg/ml hydrocortisone before transferring
to Lab-Tek 11 chamber slides (Thermo Fisher Scientific) at 80–
90% confluence to grow overnight. For immunofluorescence
labeling, each experimental and control group consisted of DSPP
labeling following established protocol. Briefly, cell were washed
one time with 1XPBS, fixed with 4% paraformaldhyde (PFA) for
10 min, washed 3X with PBS before permeabilizing with 0.5%
Triton X (in 1XPBS) solution for 5 min at room temperature
(RT). Cells were then incubated with DSPP primary antibody,
overnight. After washing with PBS, cells were incubated with
fluoresceine-conjugated secondary antibodies for 1 h. Thereafter,
cells were washed and mounted with VectaShield mounting
medium with 49,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories) and visualized at 1006magnification using a Nikon
inverted fluorescent microscope equipped with deconvolution
software (Slidebook 4.0, Intelligent Imaging, Denver, CO, USA).
The number of cells expressing DSPP was evaluated visually by
two observers in 10 random fields containing at least 200 cells
each. Representative photographic images were taken using a
laser-scanning confocal microscope as well as a light microscope.
In vivo anti-tumor effects of DSPP-silencing in OSC2 cells
Homozygous Balb/c nu/nu athymic female mice (4–6 weeks of
age) were purchased from the National Cancer Institute (Bethesda,
MD) and maintained at 22–24uC under pathogen-limiting
conditions as required. All animal manipulations were carried
out in a laminar airflow biological safety cabinet. Cages, bedding,
and food were autoclaved before use. Sterile water was provided
ad lib. Five million exponentially growing DSPP-silenced OSC2
cells (L2) and their scarmbled sequence (shC) control counterpart
were mixed in matrigel and media before injecting intraperitone-
ally into left and right flanks of the 2 mice, respectively. Thereafter
tumor sizes were monitored and measured weekly for 6 weeks.
Volume of the tumor was calculated using the formula (1/
2)*A*B*B, where ‘‘A’’ is the length of tumor and ‘‘B’’ breadth of
tumor. A scatter graph of tumor volume (mm3) versus weeks was
generated as Supplementary Figure S1. At the end of the
experimental period, animals were sacrificed, and tumors dissected
for Histology.
Immunohistochemistry
Paraffin block sections (5 mm) from L2– and shC-derived
tumors were immunostained for DSPP using the Nemesis 7200
automated system (BioCare; San Francisco, CA) supplied with
Super-Picture-Perfect Broad-Spectrum HRP-Polymer and Single-
Solution-AEC reagents from Zymed Lab Inc. (San Francisco, CA).
Immunostaining was carried out using established and published
protocol from our laboratory [9,10]. For negative controls we
substituted non-immune mouse IgG control (Zymed) in place of
primary antibody (LFMb21). Photographic representative results
for each case were captured using the Axioplan 2 Universal
microscope equipped with an Axiovision camera and program
(Carl Zeiss Gmbh, Jena, Germany).
Statistical analysis
Data are expressed as mean 6 SD. Statistical analysis was
performed using SigmaStat Version 3 (Systat software, Point
Richmond, CA) and SAS 9.1 (SAS Institute, Inc., Cary, NC). Due
to the skewed nature of the data, the Kruskal-Wallis test and Dunn
multiple comparisons were used any time more than two groups
were compared. Least-squares regression through the origin was
used to describe the relationship between the degree of DSSP
silencing and the level of suppression of each of the three
SIBLING-partnering MMPs, and to compare this relationship
between pro-MMP and cleaved MMP. The criterion for
significance was P,0.05 for all statistical tests.
Supporting Information
Figure S1 In vivo anti-tumor effects of DSPP-silencing in OSC2
cells. (A) The anti-tumor effect of DSPP-silencing in OSC2 cells
shows small tumor size (volume) for L2 derived tumor (left flank)
compared with shC control derived tumors (right flank). Tumor
size was measured weekly over a period of 6 weeks. (B) Histologic
evaluation of hematoxylene and eosin (H&E) sections showing well
differentiated and aggressive squamous cell carcinoma (arrow)
associated with the shC (control) derived tumors. (C) Less-
differentiated L2 derived tumors formed small shrinking islands
(*) and tumor necrosis compared with shC tumors (B). (D)
Immuostain for DSPP with LF-Mb21 antibody verified significant
DSPP reduction in L2 derived tumors compared with high DSPP
level (brown stain) in shC derived tumors (E). (F) A representative
pre-immune IgG negative control. (G) Scatter plot of growth trend
for L2 derived tumors (red) and the shC derived tumors (blue)
showing slowed tumor development and volume for L2 tumor
compared with shC tumors over a period of 6 weeks.
Found at: doi:10.1371/journal.pone.0013974.s001 (2.39 MB TIF)
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